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What is already known about this subject {#bcp14038-sec-0006}
========================================

Due to its favourable toxicity and side effect profile, cannabidiol is under increasing investigation in the commercial and medical industry to treat many clinical indications.

What this study adds {#bcp14038-sec-0007}
====================

This study identifies the wide active dosing range of cannabidiol (\<1 to 50 mg/kg/d) within a variety of medical conditions including epilepsy, anxiety and graft‐*vs*‐host disease.This review indicates that studies that used higher doses tended to have better therapeutic outcomes compared to lower doses overall.This study identifies a strong existing need for dose‐ranging clinical studies to be conducted in which plasma concentrations can provide a better indication of the therapeutic range of cannabidiol.

1. INTRODUCTION {#bcp14038-sec-0008}
===============

Cannabidiol (CBD) is a non‐intoxicating major constituent of the Cannabis sativa plant that has been increasing in interest due to its potentially diverse range of therapeutic properties and its favourable safety and tolerability profile.[1](#bcp14038-bib-0001){ref-type="ref"} Side effects are generally mild and infrequent, such as sleepiness, diarrhoea or increased temperature. It is also reported that clinically significant drug‐interactions pose a low risk.[2](#bcp14038-bib-0002){ref-type="ref"} There is no evidence for dependency or abuse potential with CBD use, as concluded by the World Health Organisation Expert Committee on Drug Dependence.[1](#bcp14038-bib-0001){ref-type="ref"} The purported effects of CBD include analgesic, anti‐inflammatory, antioxidant, anxiolytic, anticonvulsant and cytotoxic effects, which are mediated through signalling mechanisms including the cannabinoid receptor 1 (weak agonist), the cannabinoid receptor 2 (inverse agonist), the serotonin 1a receptor (5‐HT~1A~), G protein‐coupled receptor 55 (GPR55), G protein‐coupled receptor 18 (GPR18) and the transient receptor potential cation channel subfamily V member 1 (TRPV1) receptors, amongst others.[3](#bcp14038-bib-0003){ref-type="ref"}

Clinically, CBD is being investigated in multiple disease states including neurodegeneration, anxiety disorder, orphan childhood diseases with a prevalence of \<5 in 10 000 individuals (e.g. tuberous sclerosis complex) and addiction (ongoing trials in cannabis and cocaine craving).[4](#bcp14038-bib-0004){ref-type="ref"}, [5](#bcp14038-bib-0005){ref-type="ref"}, [6](#bcp14038-bib-0006){ref-type="ref"} Epidiolex has recently become the first Food and Drug Administration‐approved CBD medicine, indicated for use in Lennox--Gastaut or Dravet syndrome (childhood epilepsy) by oral administration. Sativex is an oromucosal spray containing both CBD and δ‐9‐tetrahydrocannibinol, which is licenced in the EU and Canada for the treatment of multiple sclerosis associated spasticity. At the time of writing, there are 49 clinical trials registered on [clinicaltrials.gov](http://clinicaltrials.gov) investigating CBD alone (either not yet recruiting, recruiting or active) and there have been at least a further 100 clinical trials previously registered containing CBD, indicating a significant clinical interest with an ongoing need to ensure that human volunteers engaged in these trials are given doses that are optimised for efficacy and safety. Surprisingly, none of the 49 currently registered trials have explicitly included a study design to investigate the dose‐ranging efficacy of CBD.

Hemp‐derived CBD is commercially available and is currently used as a health and food supplement commonly for anxiety and pain relief. This market represents a flourishing industry expected to rise financially and globally.[7](#bcp14038-bib-0007){ref-type="ref"} However, the blurred lines between CBD as a licensed medicine and CBD as an over‐the‐counter remedy contribute to the overall lack of understanding of what dose of CBD may be considered *therapeutic*. This is further hampered by the lack of standardisation in over‐the‐counter CBD products and their unregulated labelled doses.

Despite the prevalence of CBD use and current hype, guidance on dose recommendations has not advanced and is not clear, additionally hampered by the striking lack of accessible pharmacokinetic and bioavailability data of CBD in humans.[8](#bcp14038-bib-0008){ref-type="ref"} No published study to date has reported the absolute oral bioavailability of CBD in humans.[8](#bcp14038-bib-0008){ref-type="ref"} Limited dose‐determination studies have left a paucity in data surrounding desired plasma concentrations to achieve minimum effective doses. Additionally, the lack of information on the role of different formulations and routes of administration on absorption are also apparent. The aim of this review was to comprehensively collate all published data relating to CBD administration in clinical populations to describe the range of CBD doses assessed across different pathological states.

2. METHODS {#bcp14038-sec-0009}
==========

2.1. Search strategy {#bcp14038-sec-0010}
--------------------

The systematic review was carried out in accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses) guidelines. A systematic search of PubMed, EMBASE (including MEDLINE) and [clinicaltrials.gov](http://clinicaltrials.gov) was conducted to retrieve all articles reporting CBD administration in clinical populations using 'CBD or Cannabidiol' as search terms. Searches were restricted to 'humans' and 'clinical trials and case reports' in PubMed and EMBASE, with no restrictions on [clinicaltrials.gov](http://clinicaltrials.gov). The searches were carried out by 8 August 2018 by 2 independent researchers.

2.2. Eligibility criteria {#bcp14038-sec-0011}
-------------------------

The titles and abstracts of retrieved studies were examined by 2 independent researchers, and inappropriate articles were rejected. Inclusion criteria were as follows: an original, peer‐reviewed published paper that involved administration of CBD to a clinical population, or reported on [clinicaltrials.gov](http://clinicaltrials.gov), and included an outcome measurement to assess the efficacy of CBD i.e. improvement in disease. Exclusion criteria were: administration in healthy participants only; CBD administered in combination with other cannabinoids such as with δ‐9‐tetrahydrocannibinol or as whole cannabis extracts; article not in English; no stated concentration of CBD used; or no statistical results reported. The reference lists of included studies were hand‐searched for additional relevant studies.

2.3. Data acquisition and analysis {#bcp14038-sec-0012}
----------------------------------

The included articles were analysed, and the following data extracted: sample size, clinical population/medical context; study design and length; administration route of CBD; source of CBD; dose of CBD; side effects; and primary outcome results. All data entry was checked by an additional independent researcher. Risk of bias of the 15 randomised controlled trials was assessed using the 2011 Cochrane Collaboration\'s tool for assessing risk of bias.

As this review included studies of participants of all ages (from infants to adults), dosing is reported in mg/kg of body weight to allow for comparison. Where not available as mg/kg (24 studies), dose was converted for adults using an average adult body weight of 62 kg.[9](#bcp14038-bib-0009){ref-type="ref"} In only 1 publication, a case report on a child, an average child weight of 40 kg had to be used to convert reported mg/d dose into mg/kg/d.[10](#bcp14038-bib-0010){ref-type="ref"}

A positive effect of CBD was determined by the presence of a significant improvement in primary end points(s) or outcomes reported compared to placebo or baseline. A lack of positive effect was determined if no significant improvements were reported. Mixed findings were reported for example in case reports wherein some patients improved, others did not, or where a primary outcome was not specified (exploratory study) and in which some endpoints improved while others worsened (1 study) or remained unchanged.

3. RESULTS {#bcp14038-sec-0013}
==========

The initial search yielded 1038 records, from which 896 abstracts were reviewed, and 35 articles were included in the final analysis, comprising a total number of 1223 participants. A flow chart of article retrieval and selection is presented in Figure [1](#bcp14038-fig-0001){ref-type="fig"}. Fifteen studies were randomised controlled trials (RCTs), 8 were clinical trials but not both randomised and controlled in design (for example open‐label trials), and 12 articles were case reports/series. A description of each study is presented in tables [1](#bcp14038-tbl-0001){ref-type="table"}, [2](#bcp14038-tbl-0002){ref-type="table"}, [3](#bcp14038-tbl-0003){ref-type="table"} according to study design. Results of the risk of bias assessment of the RCTs are presented in Figure [2](#bcp14038-fig-0002){ref-type="fig"}. A component of blinding was included in 74% of the RCTs . No study was reported with a high risk of selection bias, detection bias, or reporting bias. Overall, most information was from studies at low risk of bias. No study reported plasma concentrations of CBD. All studies reported oral administration of CBD, either as an oral solution (*n* = 11), capsules (*n* = 13), spray/sublingual (*n* = 4), or orally but unspecified (*n* = 6).

![Flow chart of study retrieval and selection](BCP-85-1888-g001){#bcp14038-fig-0001}

###### 

Summary of included studies: randomised controlled trials

  Study                                                                                               Clinical population                                            Total n   Design                                                                                            Trial length       CBD dose (mg) and approx. mg/kg/d[a](#bcp14038-note-0001){ref-type="fn"}   Route of admin.      CBD source    Results[b](#bcp14038-note-0002){ref-type="fn"}: Primary endpoint(s)                                                                                                                                                                                                                                                                           \+ effect   Side effects
  --------------------------------------------------------------------------------------------------- -------------------------------------------------------------- --------- ------------------------------------------------------------------------------------------------- ------------------ -------------------------------------------------------------------------- -------------------- ------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------- ------------------------------------------------------------------------------------------------------------------------------------------------------
  **McGuire, 2018 (NCT02006628)** [11](#bcp14038-bib-0011){ref-type="ref"}                            Schizophrenia, adults                                          88        Phase II exploratory double‐blind, parallel‐group, RCT. Add‐on therapy to anti‐psychotic drugs.   8 wk               1000 mg/d (16.7 mg/kg/d)                                                   Oral solution        GW            Positive psychotic symptoms reduced. Negative, overall and general psychotic symptoms unchanged. Higher proportion of CBD treated patients rated as *improved*. No differences in functionality. No significant improvement in cognitive function except for motor speed. Overall reported as clinically significant improvements with CBD.   Yes         Rates of adverse events similar between CBD and placebo groups
  **Thiele, 2018 (NCT02224690)** [12](#bcp14038-bib-0012){ref-type="ref"}                             Seizures (Lennox--Gastaut syndrome), ages 2--55 y              171       Double‐blind, phase III, RCT. Add‐on therapy to AEDs.                                             14 wk              20 mg/kg/d                                                                 Oral solution        GW            Monthly frequency of drop seizures decreased by a median of 43.9% in the CBD group, significantly more than in the placebo group                                                                                                                                                                                                              Yes         Diarrhoea, somnolence, pyrexia, decreased appetite, vomiting
  **Devinsky, 2018 (NCT02224560)** [13](#bcp14038-bib-0013){ref-type="ref"}                           Lennox--Gastaut syndrome (epilepsy), ages 2--55 y              225       Phase III, double‐blind, RCT. Add‐on therapy to AEDs.                                             14 wk              10 or 20 mg/kg/d                                                           Oral solution        GW            Significantly greater reduction in CBD groups in drop seizure frequency than in placebo                                                                                                                                                                                                                                                       Yes         9% taking CBD had elevated liver aminotransferases. Somnolence, decreased appetite, diarrhoea, upper respiratory tract infection, pyrexia, vomiting.
  **Boggs, 2018 (NCT00588731)** [14](#bcp14038-bib-0014){ref-type="ref"}                              Schizophrenia, adults                                          36        Double‐blind, parallel group, RCT. Add‐on therapy to anti‐psychotic drugs.                        6 wk               600 mg/d (10 mg/kg/d)                                                      Oral capsules        STI           No effect on cognition or symptoms                                                                                                                                                                                                                                                                                                            No          Similar rates between placebo and CBD, with exception of sedation which was higher in CBD group.
  **Naftali, 2017 (NCT01037322)** [15](#bcp14038-bib-0015){ref-type="ref"}                            Crohn\'s disease, adults                                       19        RCT                                                                                               8 wk               20 mg/d (0.3 mg/kg/d)                                                      Orally, sublingual   On‐site       No difference in disease index                                                                                                                                                                                                                                                                                                                No          None observed
  **Devinsky, 2017 (NCT02091375)** [16](#bcp14038-bib-0016){ref-type="ref"}                           Treatment resistant Dravet syndrome (epilepsy), aged 2--18 y   120       Double‐blind, RCT. Add‐on therapy to AEDs.                                                        14 wk              20 mg/kg/d                                                                 Oral solution        GW            Reduction in frequency of convulsive seizures compared to baseline, significantly greater reduction than with placebo                                                                                                                                                                                                                         Yes         Diarrhoea, vomiting, fatigue, pyrexia, somnolence, abnormal results on liver‐function: tests were higher in the CBD group than placebo
  **Jadoon, 2016 (NCT01217112)** [17](#bcp14038-bib-0017){ref-type="ref"}                             Type 2 diabetes patients, adults                               62        Double‐blind, RCT                                                                                 13 wk              200 mg/d (3.3 mg/kg/d)                                                     Oral                 GW            No change in HDL‐cholesterol concentrations or glycaemic control.                                                                                                                                                                                                                                                                             No          Well tolerated
  **Chagas, 2014** [18](#bcp14038-bib-0018){ref-type="ref"}                                           Parkinson\'s disease, adults                                   21        Double‐blind exploratory RCT. Add‐on therapy to anti‐Parkinson\'s drugs.                          6 wk               75 or 300 mg/d (1.25 or 5 mg/kg/d)                                         Oral capsules        THC           No effect on motor and general symptoms; 300‐mg dose improved well‐being and quality of life scores.                                                                                                                                                                                                                                          Mixed       None reported
  **Leweke, 2012** [19](#bcp14038-bib-0019){ref-type="ref"}                                           Schizophrenia, adults                                          42        Phase II, double‐blind, parallel‐group, RCT                                                       4 wk               800 mg/d (max: 13.3 mg/kg/d)                                               NA                   NA            Significant improvement of psychotic symptoms compared to baseline                                                                                                                                                                                                                                                                            Yes         Well tolerated
  **Bergamaschi, 2011** [20](#bcp14038-bib-0020){ref-type="ref"}                                      Generalised SAD, adults                                        24        Double‐blind, RCT                                                                                 Acute              600 mg (10 mg/kg)                                                          Oral capsule         STI and THC   Reduction in anxiety, cognitive impairment, discomfort in speech performance. Alert factors in anticipatory speech were also reduced.                                                                                                                                                                                                         Yes         None reported
  **Tomida, 2006** [21](#bcp14038-bib-0021){ref-type="ref"}                                           Ocular hypertension, adults                                    6         Double‐blind, 4‐way cross‐over, RCT                                                               Acute              20 or 40 mg (0.3 or 0.7 mg/kg)                                             Oromucosal spray     GW            20 mg of CBD was ineffective, while 40 mg slightly increased intraocular pressure.                                                                                                                                                                                                                                                            No          Mild---e.g. oral discomfort.
  **Notcutt, 2004** [22](#bcp14038-bib-0022){ref-type="ref"}                                          Chronic pain, adults                                           24        Double‐blind, 4‐way cross‐over, RCT. Add‐on therapy to pain medication.                           8 wk               Approx. 9 sprays/d, equivalent of 22.5 mg/d (0.4 mg/kg/d)                  Sublingual spray     GW            Symptom control or sleep duration was not improved with CBD; however, sleep quality was.                                                                                                                                                                                                                                                      No          Mid---drowsiness, dry mouth
  **Consroe, 1991** [23](#bcp14038-bib-0023){ref-type="ref"}                                          Huntington\'s disease, adults                                  15        Double‐blind, cross‐over, RCT                                                                     6 wk               10 mg/kg/d                                                                 Oral capsules        US NIDA       CBD was ineffective                                                                                                                                                                                                                                                                                                                           No          Similar between CBD and placebo
  **Cunha, 1980** [24](#bcp14038-bib-0024){ref-type="ref"}                                            Epilepsy, adults                                               15        Double‐blind, RCT study. Add‐on therapy to AEDs.                                                  Up to 4.5 months   200--300 mg/d (5 mg/kg/d)                                                  Oral capsules        NA            All but 1 patient improved condition                                                                                                                                                                                                                                                                                                          Yes         Well tolerated
  [\*](#bcp14038-note-0003){ref-type="fn"} **NCT01284634** [25](#bcp14038-bib-0025){ref-type="ref"}   Fatty liver disease, adults                                    25        Partially‐blinded, phase II, RCT                                                                  8 wk               200, 400 or 800 mg/d (3.3, 6.7, or 13.3 mg/kg/d)                           Oral capsules        GW            No differences in liver triglyceride levels                                                                                                                                                                                                                                                                                                   No          Similar between CBD and placebo

If not supplied, mg/kg/d was calculated based on average adult weight of 62 kg to enable comparisons.

Significant compared to placebo/control (*P* \< .05) unless stated otherwise.

Registered clinical trial identifier: not published in any peer‐reviewed journal but results available from [clinicaltrials.gov](http://clinicaltrials.gov).

AEDs, anti‐epileptic drugs; CBD, cannabidiol; GW, GW Pharmaceuticals; HDL, high density lipoprotein; NA, not available; NIDA, National Institute on Drug Abuse; RCT, randomised controlled trial; SAD, social anxiety disorder; STI, STI Pharmaceuticals; THC, THC Pharm.

###### 

Summary of included studies: clinical studies

  Study                                                                       Clinical population                                              Total n   Design                                   Trial length   CBD dose (mg) and approx. mg/kg/d[a](#bcp14038-note-0005){ref-type="fn"}       Route of admin.                    CBD source   Results[b](#bcp14038-note-0006){ref-type="fn"}: Primary endpoint(s)                                        \+ effect   Side effects
  --------------------------------------------------------------------------- ---------------------------------------------------------------- --------- ---------------------------------------- -------------- ------------------------------------------------------------------------------ ---------------------------------- ------------ ---------------------------------------------------------------------------------------------------------- ----------- -------------------------------------------------------------------------------------------
  **Rosenberg, 2017** [26](#bcp14038-bib-0026){ref-type="ref"}                Epilepsy, 1--30 y                                                48        Open label clinical study                12 wk          2--5 mg/kg/d titrated up to 50 mg/kg/d or intolerance                          Oral solution or by gastric tube   GW           Improvement in quality of life as well as some cognitive functions (memory and control)                    Yes         Somnolence, drowsiness, fatigue
  **Devinsky, 2016** [27](#bcp14038-bib-0027){ref-type="ref"}                 Drug‐resistant epilepsy, ages 1--30 y                            137       Prospective, open‐label trial            12 wk          2--5 mg/kg/d, up‐titrated to 25 or 50 mg/kg/d                                  Oral solution or gastric tube      GW           Monthly motor seizures reduced by a median of 35.5% from baseline                                          Yes         Somnolence, fatigue, diarrhoea, decreased appetite, weight loss, status epilepticus (6%).
  **Hess, 2016** [28](#bcp14038-bib-0028){ref-type="ref"}                     Drug‐resistant epilepsy in tuberous sclerosis complex, 2--31 y   18        Prospective study                        6--12 months   5 mg/kg/d titrated up to 50 mg/kg/d if tolerated                               Oral solution                      GW           Decreased seizure frequency                                                                                Yes         Drowsiness, ataxia, diarrhoea
  **Yeshurun, 2015 (NCT01385124)** [29](#bcp14038-bib-0029){ref-type="ref"}   Cell transplant, (GVHD), adults                                  48        Prospective, phase II clinical trial     37‐day         300 mg/d (5 mg/kg/d)                                                           Oral solution                      STI          No patients developed acute GVHD. Significantly reduced risk ratio compared to historical case controls.   Yes         None reported
  **Crippa, 2011** [5](#bcp14038-bib-0005){ref-type="ref"}                    Generalised SAD, adults                                          10        Double‐blind, placebo‐controlled study   Acute          400 mg (6.7 mg/kg)                                                             Oral capsule                       THC          Reduced subjective anxiety                                                                                 Yes         None reported
  **Hallak, 2010** [30](#bcp14038-bib-0030){ref-type="ref"}                   Schizophrenia, adults                                            28        Placebo‐controlled study                 Acute          300 or 600 mg (5 or 10 mg/kg)                                                  Oral capsules                      Gift         No beneficial effects on selective attention                                                               No          None reported
  **Zuardi, 2009** [31](#bcp14038-bib-0031){ref-type="ref"}                   Psychosis in Parkinson\'s disease, adults                        6         Open‐label pilot study                   4 wk           150 mg/d, increased by 150 mg each week to a total of 400 mg/d (6.7 mg/kg/d)   Oral capsule                       THC          Decrease in psychotic symptoms and Parkinson\'s disease rating compared to baseline                        Yes         None reported
  **Consroe, 1986** [32](#bcp14038-bib-0032){ref-type="ref"}                  Dystonic movement disorder, adults                               5         Preliminary open pilot study             6 wk           100--600 mg/d, increased weekly (1.7--10 mg/kg/d)                              Oral capsules                      NA           Dose‐related improvement in dystonia disability                                                            Yes         Mild---drop in standing blood pressure

If not supplied, mg/kg/d was calculated based on average adult weight of 62 kg to enable comparisons.

Significant compared to placebo/control (*P* \< .05) unless stated otherwise.

CBD, cannabidiol; GW, GW Pharmaceuticals; GVHD, graft‐vs‐host disease; STI, STI Pharmaceuticals; SAD, social anxiety disorder; THC, THC Pharm.

###### 

Summary of included studies: case studies

  Study                                                          Clinical population                                       Total n   Design                   Trial length               CBD dose (mg) and approx. mg/kg/d[a](#bcp14038-note-0008){ref-type="fn"}   Route of admin.          CBD source       Results[b](#bcp14038-note-0009){ref-type="fn"}: Primary endpoint(s)                                    \+ effect   Side effects
  -------------------------------------------------------------- --------------------------------------------------------- --------- ------------------------ -------------------------- -------------------------------------------------------------------------- ------------------------ ---------------- ------------------------------------------------------------------------------------------------------ ----------- -----------------------------------------------------
  **Kaplan, 2017** [33](#bcp14038-bib-0033){ref-type="ref"}      Refractory seizures in Sturge--Weber syndrome, children   5         Case‐series              14 wk                      5--25 mg/kg/d                                                              Oral solution            GW               Decreases in seizure frequency                                                                         Yes         Mild
  **Warren, 2017** [34](#bcp14038-bib-0034){ref-type="ref"}      Brain tumour related epilepsy, aged 17--40 y              3         Case series              2--10 mo                   10--50 mg/kg/d                                                             Oral                     GW               Improvement in seizure frequency (n = 2) and severity (*n* = 3)                                        Yes         Diarrhoea
  **Gofshteyn, 2017** [35](#bcp14038-bib-0035){ref-type="ref"}   Febrile infection‐related epilepsy syndrome, children     7         Open‐label case series   Acute and up to 48 weeks   15--25 mg/kg/d                                                             Oral solution            GW               Improvements in frequency and duration of seizures                                                     Yes         Dizziness, decreased appetite, weight loss
  **Shannon, 2016** [10](#bcp14038-bib-0010){ref-type="ref"}     Anxiety and insomnia in PTSD, child                       1         Case report              5 mo                       25 mg/d (0.6 mg/kg/d)                                                      Oral capsule and spray   CannaVest Corp   Increased sleep quality and duration, and decreased anxiety secondary to PTSD                          Yes         None observed
  **Saade, 2015** [36](#bcp14038-bib-0036){ref-type="ref"}       Seizures, 10‐month old infant                             1         Case report              6 mo                       25 mg/kg/d                                                                 Oral solution            GW               Substantial reductions in seizures                                                                     Yes         None reported
  **Chagas, 2014** [37](#bcp14038-bib-0037){ref-type="ref"}      RBD in Parkinson\'s disease, adults                       4         Case series              6 wk                       75 mg/d (1.25 mg/kg/d)                                                     NA                       NA               Substantial reduction in RBD‐associated events compared to baseline                                    Yes         None reported
  **Crippa, 2013** [38](#bcp14038-bib-0038){ref-type="ref"}      Cannabis dependency, adult                                1         Case report              10 d                       300 mg/d increased to 600 mg/d (5--10 mg/kg/d)                             Oral capsule             THC              Absence of withdrawal symptoms                                                                         Yes         None reported
  **Zuardi, 2010** [39](#bcp14038-bib-0039){ref-type="ref"}      Bipolar disorder, adults                                  2         Case series              30 d                       600 mg/d increased to 1200 mg/d (20 mg/kg/d)                               Oral                     STI and THC      CBD was ineffective for manic episode                                                                  No          None observed
  **Zuardi, 1995** [40](#bcp14038-bib-0040){ref-type="ref"}      Schizophrenia, adult                                      1         Case report              4 wk                       1500 mg/d (25 mg/kg/d)                                                     Oral capsules            NA               Improvements in psychiatric ratings                                                                    Yes         Well tolerated; none reported
  **Zuardi, 2006** [41](#bcp14038-bib-0041){ref-type="ref"}      Treatment‐resistant schizophrenia, adults                 3         Case series              30 d                       40 mg/d, increased to 1280 mg/d (21.3 mg/kg/d)                             Oral                     GW               1 patient showed mild improvement to baseline and discontinuing treatment worsened symptoms            No          Well tolerated; none observed
  **Snider, 1985** [42](#bcp14038-bib-0042){ref-type="ref"}      Parkinson\'s disease, adult                               1         Case report              4 wk                       100--400 mg/d (3.3 mg/kg/d)                                                Oral                     NA               Improvement of dyskinesia up to 200 mg/d, worsening of Parkinson disease symptoms with 300--400 mg/d   Mixed       Dizziness, drowsiness, increased Parkinson symptoms
  **Snider, 1984** [43](#bcp14038-bib-0043){ref-type="ref"}      Meige syndrome, adult                                     1         Case report              Long‐term                  Initially 100 mg/d increased to 400 mg/d (6.6 mg/kg/d)                     Oral                     NA               50% improvement in spasm frequency and severity                                                        Yes         Dry mouth, headache, sedation

If not supplied, mg/kg/d was calculated based on average adult weight of 62 kg to enable comparisons.

Significant compared to placebo/control (*P* \< .05) unless stated otherwise.

CBD, cannabidiol; GW, GW Pharmaceuticals; PTSD, post‐traumatic stress disorder; RBD, rapid eye movement sleep behaviour disorder; STI, STI Pharmaceuticals; THC, THC Pharm.

![Risk of bias summary of the randomised controlled trials included in the systematic review. Green indicates low‐risk bias, red indicates high‐risk bias, and yellow indicates intermediate or unclear risk](BCP-85-1888-g002){#bcp14038-fig-0002}

Of the 15 RCTs, the range of doses investigated varied from \<1 mg/kg up to 20 mg/kg per day (average 9 mg/kg/d).[11](#bcp14038-bib-0011){ref-type="ref"}, [12](#bcp14038-bib-0012){ref-type="ref"}, [13](#bcp14038-bib-0013){ref-type="ref"}, [14](#bcp14038-bib-0014){ref-type="ref"}, [15](#bcp14038-bib-0015){ref-type="ref"}, [16](#bcp14038-bib-0016){ref-type="ref"}, [17](#bcp14038-bib-0017){ref-type="ref"}, [18](#bcp14038-bib-0018){ref-type="ref"}, [19](#bcp14038-bib-0019){ref-type="ref"}, [21](#bcp14038-bib-0021){ref-type="ref"}, [22](#bcp14038-bib-0022){ref-type="ref"}, [23](#bcp14038-bib-0023){ref-type="ref"}, [24](#bcp14038-bib-0024){ref-type="ref"}, [25](#bcp14038-bib-0025){ref-type="ref"} Seven RCTs reported CBD efficacy (average dose 14 mg/kg/d),[11](#bcp14038-bib-0011){ref-type="ref"}, [12](#bcp14038-bib-0012){ref-type="ref"}, [13](#bcp14038-bib-0013){ref-type="ref"}, [16](#bcp14038-bib-0016){ref-type="ref"}, [19](#bcp14038-bib-0019){ref-type="ref"}, [20](#bcp14038-bib-0020){ref-type="ref"}, [24](#bcp14038-bib-0024){ref-type="ref"} 7 studies describe neutral effects of CBD (average dose 5 mg/kg/d)[14](#bcp14038-bib-0014){ref-type="ref"}, [15](#bcp14038-bib-0015){ref-type="ref"}, [17](#bcp14038-bib-0017){ref-type="ref"}, [21](#bcp14038-bib-0021){ref-type="ref"}, [22](#bcp14038-bib-0022){ref-type="ref"}, [23](#bcp14038-bib-0023){ref-type="ref"}, [25](#bcp14038-bib-0025){ref-type="ref"} and 1 study showed both positive and negative outcomes.[18](#bcp14038-bib-0018){ref-type="ref"} In the remaining 8 clinical trials of various study design, 7 studies reported CBD positively (average dosing 23 mg/kg/d)[5](#bcp14038-bib-0005){ref-type="ref"}, [26](#bcp14038-bib-0026){ref-type="ref"}, [27](#bcp14038-bib-0027){ref-type="ref"}, [28](#bcp14038-bib-0028){ref-type="ref"}, [29](#bcp14038-bib-0029){ref-type="ref"}, [31](#bcp14038-bib-0031){ref-type="ref"}, [32](#bcp14038-bib-0032){ref-type="ref"} and 1 study was neutral (8 mg/kg/d).[30](#bcp14038-bib-0030){ref-type="ref"} Within the 12 case studies and case series, 9 described positive effects of CBD (average dosing 16 mg/kg/d),[10](#bcp14038-bib-0010){ref-type="ref"}, [33](#bcp14038-bib-0033){ref-type="ref"}, [34](#bcp14038-bib-0034){ref-type="ref"}, [35](#bcp14038-bib-0035){ref-type="ref"}, [36](#bcp14038-bib-0036){ref-type="ref"}, [37](#bcp14038-bib-0037){ref-type="ref"}, [38](#bcp14038-bib-0038){ref-type="ref"}, [40](#bcp14038-bib-0040){ref-type="ref"}, [43](#bcp14038-bib-0043){ref-type="ref"} 2 were neutral (average dosing 21 mg/kg/d)[39](#bcp14038-bib-0039){ref-type="ref"}, [41](#bcp14038-bib-0041){ref-type="ref"} and 1 study described mixed results (3 mg/kg/d).[42](#bcp14038-bib-0042){ref-type="ref"}

Epilepsy was the most frequently studied medical condition, with all 11 studies describing beneficial effects of CBD in reducing the severity or frequency of seizures.[12](#bcp14038-bib-0012){ref-type="ref"}, [13](#bcp14038-bib-0013){ref-type="ref"}, [16](#bcp14038-bib-0016){ref-type="ref"}, [24](#bcp14038-bib-0024){ref-type="ref"}, [26](#bcp14038-bib-0026){ref-type="ref"}, [27](#bcp14038-bib-0027){ref-type="ref"}, [28](#bcp14038-bib-0028){ref-type="ref"}, [33](#bcp14038-bib-0033){ref-type="ref"}, [34](#bcp14038-bib-0034){ref-type="ref"}, [35](#bcp14038-bib-0035){ref-type="ref"}, [36](#bcp14038-bib-0036){ref-type="ref"} Within the 4 conducted RCTs (*n* = 531), an average dosing of 15 mg/kg/d was used where CBD was administered successfully as an add‐on therapy to usual anti‐epileptic drugs.[12](#bcp14038-bib-0012){ref-type="ref"}, [13](#bcp14038-bib-0013){ref-type="ref"}, [16](#bcp14038-bib-0016){ref-type="ref"}, [24](#bcp14038-bib-0024){ref-type="ref"} Significant improvements were observed compared to placebo as an add‐on therapy. Within the other 3 clinical trials of prospective open‐label design (*n* = 203), CBD was administered at an average dosing of 42 mg/kg/d and significant improvements in quality of life and seizure frequency compared to baseline were observed.[26](#bcp14038-bib-0026){ref-type="ref"}, [27](#bcp14038-bib-0027){ref-type="ref"}, [28](#bcp14038-bib-0028){ref-type="ref"} 3 case series and 1 case report (total *n* = 16) reported beneficial effects of CBD on seizure frequency, duration and severity with an average administered dose of 21 mg/kg/d.[33](#bcp14038-bib-0033){ref-type="ref"}, [34](#bcp14038-bib-0034){ref-type="ref"}, [35](#bcp14038-bib-0035){ref-type="ref"}, [36](#bcp14038-bib-0036){ref-type="ref"}

Seven studies were conducted in the context of schizophrenia and bipolar disorder. Within the RCTs, 2 conducted with an average dosing of 15 mg/kg/d over 4 or 8 weeks reported positive reductions in psychotic or psychiatric symptoms and a better side effect profile (*n* = 130).[11](#bcp14038-bib-0011){ref-type="ref"}, [19](#bcp14038-bib-0019){ref-type="ref"} One of these compared CBD against an active control (amisulpride), and the other as an add‐on therapy to usual medication compared to placebo as an add‐on therapy. However, a third RCT employing CBD as an add‐on therapy did not report any improvements in cognition or symptoms of schizophrenia after a lower average dose of 10 mg/kg/d over 6 weeks (*n* = 36).[14](#bcp14038-bib-0014){ref-type="ref"} An acute dose of 5 or 10 mg/kg/d did not improve selective attention in a placebo‐controlled trial of 28 schizophrenia patients.[30](#bcp14038-bib-0030){ref-type="ref"} A number of case studies have also been conducted by Zuardi and colleagues in this medical context. In 2 patients with bipolar disease, 20 mg/kg/d was ineffective in treating manic episodes.[39](#bcp14038-bib-0039){ref-type="ref"} CBD was similarly unable to improve symptoms in 3 schizophrenia patients, although 1 patient described mild improvement.[41](#bcp14038-bib-0041){ref-type="ref"} Another case report described improvement in psychiatric ratings following an average dose of 25 mg/kg/d over 4 weeks.[40](#bcp14038-bib-0040){ref-type="ref"}

Results are mixed within Parkinson\'s disease studies. Within an RCT in 21 patients, 1.25 or 5 mg/kg/d CBD had no effect on motor and general symptoms. However, the 5 mg/kg/d dose improved well‐being and quality of life scores.[18](#bcp14038-bib-0018){ref-type="ref"} The remaining studies are case studies in which CBD decreased psychotic symptoms and Parkinson\'s disease ratings (*n* = 6; 7 mg/kg/d),[31](#bcp14038-bib-0031){ref-type="ref"} improved rapid eye movement sleep behaviour disorder (*n* = 4; 1 mg/kg/d),[37](#bcp14038-bib-0037){ref-type="ref"} decreased dyskinesia with 2 to 3 mg/kg/d doses (*n* = 1), but exaggerated Parkinson\'s disease symptoms with 5 and 7 mg/kg/d doses.[42](#bcp14038-bib-0042){ref-type="ref"}

CBD did not change therapeutic outcome variables in a double‐blind RCT in Huntington disease patients compared to placebo (*n* = 15; 10 mg/kg/d for 6 weeks),[23](#bcp14038-bib-0023){ref-type="ref"} but improved dystonia disability in an open pilot study (*n* = 5; 10 mg/kg/d for 6 weeks),[32](#bcp14038-bib-0032){ref-type="ref"} and improved spasm frequency and severity in a case report in 1 patient with Meige syndrome (7 mg/kg/d).[43](#bcp14038-bib-0043){ref-type="ref"}

Within the RCTs, CBD did not significantly change the primary outcomes in diabetes (*n* = 62), Crohn\'s disease (*n* = 19), ocular hypertension (*n* = 6), chronic pain (mostly neuropathic; *n* = 24), or fatty liver disease (*n* = 25).[15](#bcp14038-bib-0015){ref-type="ref"}, [17](#bcp14038-bib-0017){ref-type="ref"}, [21](#bcp14038-bib-0021){ref-type="ref"}, [22](#bcp14038-bib-0022){ref-type="ref"}, [25](#bcp14038-bib-0025){ref-type="ref"} However, an average dose of 2.4 mg/kg/d (range 0.3--13.3 mg/kg/d) was used in these studies, which is very low in the clinical and clinical trial setting compared to other studies. Low doses (10 mg/kg) did, however, produce positive responses in generalised social anxiety disorder (SAD) in a double‐blind RCT in 24 patients.[20](#bcp14038-bib-0020){ref-type="ref"} Likewise, in another double‐blind placebo‐controlled study, a dose of 6.7 mg/kg reduced subjective anxiety in 10 adults with generalised SAD.[5](#bcp14038-bib-0005){ref-type="ref"} Additionally, in a case report in a child, 0.6 mg/kg/d increased sleep quality and duration, and decreased anxiety secondary to PTSD.[10](#bcp14038-bib-0010){ref-type="ref"}

Lastly, it was found that doses of 5 mg/kg/d prevented occurrence of graft‐*vs*‐host disease in a phase II clinical trial (*n* = 48) and 5--10 mg/kg/d doses have been shown in a case report to remove withdrawal symptoms from a patient with cannabis dependency.[29](#bcp14038-bib-0029){ref-type="ref"}, [38](#bcp14038-bib-0038){ref-type="ref"}

Within studies that compared CBD against a placebo or control (*n* = 17 publications), only 1 compared CBD against an active control (and a greater clinical improvement and side effect profile was observed with CBD against amisulpride), 8 compared CBD against a placebo (monotherapy), and 8 studies compared CBD as an add‐on therapy (adjunctive to antipsychotic medication, antiepileptic medication, anti‐Parkinson medication or pain medication) against placebo. Analysis of these data revealed that a greater proportion of studies reported a beneficial effect of CBD in the add‐on therapy group compared to the monotherapy group (*n* = 6 and *n* = 2 respectively). However, higher doses were used overall within the add‐on therapy group compared to the monotherapy group (average 11 and 6 mg/kg/d, respectively) and, due to such a small data set and heterogeneity of studies, we did not perform any further analysis.

4. DISCUSSION {#bcp14038-sec-0014}
=============

To our knowledge, this is the first study to compile and compare all publications in which CBD was administered to clinical populations. The aim of this systematic review was to better understand the range of doses of CBD used in clinical studies. In total, 13 medical contexts were included in this review amongst 35 studies including clinical trials and case reports. A positive effect of CBD was reported in 66% of studies, covering disorders including schizophrenia, SAD, epilepsy, cannabis dependency and graft‐*vs*‐host disease, with doses ranging between \<1 and 50 mg/kg/d (i.e. \<62--3100 mg/d for an adult). Although we acknowledge that these results mix widely heterogeneous studies, it appears well founded to highlight the differences in average dosing for positive effect studies against those without positive effects, which is confirmed when analysing studies per medical context within each study design format. This suggests that CBD potentially displays a wide therapeutic range, and variable minimum doses are required for effect depending on primary outcomes assessed and the population group. However, it is vital to note that no conclusions can be drawn on the efficacy of CBD as larger phase III and conclusive efficacy trials have not been conducted, with exception of epilepsy. A number of phase III clinical trials are registered on [clinicaltrials.gov](http://clinicaltrials.gov), which should provide more evidence in the coming years in the contexts of pain, anxiety, Crohn\'s disease, bipolar disorder, Fragile X syndrome, epilepsy and more.

CBD is increasingly popular, both as a food and health supplement and as a licensed medicine. Within this review, 51% of studies have been published in the last 5 years (since 2013); however, the included articles span over decades, with prominent publications first appearing in the 1980s and early 1990s.[24](#bcp14038-bib-0024){ref-type="ref"}, [40](#bcp14038-bib-0040){ref-type="ref"} Despite its long history of sole administration to patients, there is surprisingly little published about the pharmacokinetic properties of CBD, particularly its bioavailability, making it difficult to estimate true effective doses.[8](#bcp14038-bib-0008){ref-type="ref"} Historically, there is a striking lack of dose‐ranging studies and, looking forward, there are no registered trials on [clinicaltrials.gov](http://clinicaltrials.gov) including specific dose‐ranging investigations in their study design. Ideally, this review would have compared plasma concentrations of CBD in order to more accurately estimate therapeutic concentrations, but, due to the lack of reporting, this was not possible.

Different effective plasma concentrations of CBD may be required for achieving different endpoints across clinical populations, which is a recognised trait in a number of other drugs and diseases. For example, aspirin (acetylsalicylic acid) is used at low doses for antiplatelet therapy, and at higher doses as an analgesic agent.[44](#bcp14038-bib-0044){ref-type="ref"}, [45](#bcp14038-bib-0045){ref-type="ref"} With CBD, lower doses may be effective in anxiety relief, while higher doses may be required for effective reduction in epileptic seizures. In studies where there are good rationales for CBD use (e.g. Crohn\'s disease and chronic pain[46](#bcp14038-bib-0046){ref-type="ref"}, [47](#bcp14038-bib-0047){ref-type="ref"}), neutral results may be secondary to subtherapeutic dosing, and dose‐escalation trials with embedded pharmacokinetic studies are the next logical step.[15](#bcp14038-bib-0015){ref-type="ref"}, [22](#bcp14038-bib-0022){ref-type="ref"} Studies in this review using higher doses concluded that CBD was generally well‐tolerated with the most frequent side effects including drowsiness, nausea, somnolence, fatigue and vomiting.

Among the clinical trial records retrieved from [clinicaltrials.gov](http://clinicaltrials.gov), only 60% of completed trials had results uploaded and available. This may represent a significant publication bias and is suggestive of disregard for the priority of publication of negative results, which is a well‐recognised problem.[48](#bcp14038-bib-0048){ref-type="ref"} Unfortunately, this may potentially skew the findings presented in this review and so should be interpreted with caution and is acknowledged as a limitation. We also acknowledge that despite all routes of administration being oral, there may be further bias introduced between studies as one dose cannot be directly compared to another due to lack of standardisation of formulations and pharmacokinetic activity, including differences in bioavailability between an oral spray and an oral capsule.

Future studies should also consider the safety of drug interactions with CBD. CBD is a known inhibitor of the cytochrome P450 (CYP) system[49](#bcp14038-bib-0049){ref-type="ref"} and can therefore increase plasma concentrations of medicines already in use, in particular antiepileptic drugs. Indeed, this has been reported in a number of publications investigating concomitant use of CBD and antiepileptic drugs.[50](#bcp14038-bib-0050){ref-type="ref"} Similarly, CYP inhibitors are predicted to increase CBD plasma concentrations which should be equally monitored. Where possible, further well designed trials with CBD may disentangle whether CBD offers unique therapeutic potential in addition to benefits seen when used as an add‐on treatment.

5. CONCLUSION {#bcp14038-sec-0015}
=============

Although larger confirmatory and efficacy clinical trials examining dosing in more detail for each medical context is required, this review summarises that CBD appears to offer a wide‐range of activity between 1 and 50 mg/kg/d, and there was a tendency of studies with positive outcomes to have used higher doses of CBD. We recommend pharmacokinetic dosing schedules in subsequent trials to consider this range along with safety data and individual patient requirements. Finally, we implore all completed trial results to be made readily available so the research community can progress and learn from equally important positive and negative outcomes for the ultimate benefit of patients.
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